Publication | Closed Access

Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study

Hematological MalignancyLymphoid NeoplasiaMedicineJackpot8 Part BImmunologyPathologyImmune Checkpoint InhibitorAdult T-cell Leukemia-lymphomaImmunotherapyOncologyRadiation Oncology